pharmaceutical investing Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo Phase 1 Combination Trial
Ziopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical Assets
The Crushed Pile in Nevada: How a Forgotten 1989 Gold Heap Is Becoming One of America's Few Near-Term Antimony Solutions
